The estimated Net Worth of Jillian B. Thomsen is at least $4.71 Million dollars as of 16 February 2023. Ms. Thomsen owns over 10,267 units of Nektar Therapeutics stock worth over $391,871 and over the last 16 years she sold NKTR stock worth over $2,405,884. In addition, she makes $1,916,080 as Senior Vice President - Finance und Chief Accounting Officer at Nektar Therapeutics.
Sign up
Ms. Thomsen NKTR stock SEC Form 4 insiders trading
Jillian has made over 43 trades of the Nektar Therapeutics stock since 2014, according to the Form 4 filled with the SEC. Most recently she sold 10,267 units of NKTR stock worth $30,801 on 16 February 2023.
The largest trade she's ever made was exercising 112,500 units of Nektar Therapeutics stock on 20 March 2017 worth over $1,120,500. On average, Jillian trades about 9,003 units every 45 days since 2008. As of 16 February 2023 she still owns at least 313,497 units of Nektar Therapeutics stock.
You can see the complete history of Ms. Thomsen stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Jillian Thomsen biography
Jillian B. Thomsen serves as Senior Vice President - Finance, Chief Accounting Officer of the Company. From March 2006 through March 2008, Ms. Thomsen served as our Vice President Finance and Corporate Controller and from April 2008 through January 2010 she served as our Vice President Finance and Chief Accounting Officer. Before joining Nektar, Ms. Thomsen was Vice President Finance and Deputy Corporate Controller of Calpine Corporation from September 2002 to February 2006. Ms. Thomsen began her career as a certified public accountant at Arthur Andersen LLP, where she worked from 1990 to 2002, and specialized in audits of multinational consumer products, life sciences, manufacturing and energy companies. Ms. Thomsen holds a Masters of Accountancy from the University of Denver and a B.A. in Business Economics from Colorado College.
What is the salary of Jillian Thomsen?
As the Senior Vice President - Finance und Chief Accounting Officer of Nektar Therapeutics, the total compensation of Jillian Thomsen at Nektar Therapeutics is $1,916,080. There are 5 executives at Nektar Therapeutics getting paid more, with Jonathan Zalevsky having the highest compensation of $39,242,200.
How old is Jillian Thomsen?
Jillian Thomsen is 54, she's been the Senior Vice President - Finance und Chief Accounting Officer of Nektar Therapeutics since 2010. There are 11 older and 7 younger executives at Nektar Therapeutics. The oldest executive at Nektar Therapeutics is Dr. Brian L. Kotzin, 72, who is the Sr. VP of Clinical Devel. & Head of Immunology.
What's Jillian Thomsen's mailing address?
Jillian's mailing address filed with the SEC is C/O NEKTAR THERAPEUTICS, 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA, 94158.
Insiders trading at Nektar Therapeutics
Over the last 21 years, insiders at Nektar Therapeutics have traded over $57,608,493 worth of Nektar Therapeutics stock and bought 90,000 units worth $1,628,550 . The most active insiders traders include Howard W Robin, Gil M Labrucherie und John Nicholson. On average, Nektar Therapeutics executives and independent directors trade stock every 11 days with the average trade being worth of $36,648. The most recent stock trade was executed by Jonathan Zalevsky on 19 August 2024, trading 6,866 units of NKTR stock currently worth $8,788.
What does Nektar Therapeutics do?
nektar therapeutics is a leading biopharmaceutical company developing a robust pipeline of novel therapeutics based on its advanced polymer conjugate chemistry technology platform. nektar also partners with the top biopharmaceutical companies to bring new products to market. to date, nektar's technology and drug development expertise have enabled nine approved products for partners, which include leading biopharmaceutical companies.
What does Nektar Therapeutics's logo look like?
Complete history of Ms. Thomsen stock trades at Nektar Therapeutics
Nektar Therapeutics executives and stock owners
Nektar Therapeutics executives and other stock owners filed with the SEC include:
-
Jonathan Zalevsky,
Chief Research and Development Officer -
Howard Robin,
President, Chief Executive Officer, Director -
Gilbert Labrucherie,
Chief Financial Officer, Chief Operating Officer, Senior Vice President -
John Northcott,
Senior Vice President and Chief Commercial Officer -
Howard W. Robin,
CEO, Pres & Director -
Jillian Thomsen,
Senior Vice President - Finance, Chief Accounting Officer -
Gilbert M. Labrucherie J.D.,
Sr. VP, CFO & COO -
Dr. Jonathan Zalevsky,
Chief R&D Officer -
John P. Northcott,
Sr. VP & Chief Commercial Officer -
Mark A. Wilson,
Sr. VP, Gen. Counsel & Sec. -
Myriam Curet,
Independent Director -
Robert Chess,
Independent Chairman of the Board -
Roy Whitfield,
Lead Independent Director -
R. Scott Greer,
Independent Director -
Karin Eastham,
Independent Director -
Jeff Ajer,
Independent Director -
Dr. Brian L. Kotzin,
Sr. VP of Clinical Devel. & Head of Immunology -
Dr. Mary Tagliaferri L.Ac., M.D.,
Sr. VP & Exec. Clinical Fellow -
Jennifer Ruddock,
Sr. VP of Strategy & Corp. Affairs -
Robert Bacci,
Sr. VP of HR and Facilities -
Jillian B. Thomsen,
Sr. VP of Fin. & Chief Accounting Officer -
Lutz Lingnau,
Director -
Dennis L Winger,
Director -
Ivan P. Gergel,
SVP Drug Development & CMO -
Maninder Hora,
SVP Pharma Dev and Mfg -
Christopher A Kuebler,
Director -
Joseph J Krivulka,
Director -
Melvin Perelman,
Director -
Ajit Gill,
CEO & President -
Track Capital, Lp Deep Trac...,
-
Randall W Moreadith,
SVP Drug Development -
Bharat M Chowrira,
COO & Head of PEGylation BU -
Robert Medve,
Chief Medical Officer -
Nevan C Elam,
General Counsel and Secretary -
Timothy Harkness,
SVP & Chief Financial Officer -
John Stuart Patton,
Chief Scientific Officer -
Irwin Lerner,
Director -
Michael A/Ca Brown,
Director -
Masuoka K. Lorianne,
SVP & Chief Medical Officer -
Susan Wang,
Director -
Rinko Ghosh,
SVP & Chief Business Officer -
David Johnston,
SVP, Research & Development -
Ajay Bansal,
CFO, VP Finance & Admin -
Hoyoung Huh,
Chief Operating Officer -
J Milton Harris,
President of Nektar AL -
James B Glavin,
Director -
John Nicholson,
SVP & Chief Operating Officer -
Stephen K Doberstein,
SVP & Chief Scientific Officer -
Gil M Labrucherie,
SVP, COO & CFO -
Diana Brainard,
Director -
Mark Andrew Wilson,
Chief Legal Officer